Published in Cardiovascular Week, June 6th, 2005
According to the report from Germany, "Ischemic stroke and other atherothrombotic events substantially increase the medicoeconomic burden because of their high treatment costs and long-lasting disabilities with need for chronic care. Studies have shown that the cost of stroke represents approximately 3-5% of the annual health budget."
P.A. Ringleb and colleagues of the University of Heidelberg continued, "Antiplatelet agents play a major role in secondary stroke prevention. Acetylsalicylic acid (ASA), combined with extended-release...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.